Alicia Jenkins to Hypolipidemic Agents
This is a "connection" page, showing publications Alicia Jenkins has written about Hypolipidemic Agents.
Connection Strength
2.331
-
Relationship of low molecular weight fluorophore levels with clinical factors and fenofibrate effects in adults with type 2 diabetes. Sci Rep. 2021 09 21; 11(1):18708.
Score: 0.744
-
Triglyceride-lowering trials. Curr Opin Lipidol. 2017 Dec; 28(6):477-487.
Score: 0.571
-
The relationship of neutrophil elastase and proteinase 3 with risk factors, and chronic complications in type 2 diabetes: A Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) sub-study. Diab Vasc Dis Res. 2021 Jul-Aug; 18(4):14791641211032547.
Score: 0.183
-
Relationships of adipocyte-fatty acid binding protein and lipocalin 2 with risk factors and chronic complications in type 2 diabetes and effects of fenofibrate: A fenofibrate Intervention and event lowering in diabetes sub-study. Diabetes Res Clin Pract. 2020 Nov; 169:108450.
Score: 0.173
-
Opposite associations between alanine aminotransferase and ?-glutamyl transferase levels and all-cause mortality in type 2 diabetes: Analysis of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Metabolism. 2016 May; 65(5):783-793.
Score: 0.125
-
The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes study. Diabetologia. 2015 Mar; 58(3):464-73.
Score: 0.116
-
Favourable effects of fenofibrate on lipids and cardiovascular disease in women with type 2 diabetes: results from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetologia. 2014 Nov; 57(11):2296-303.
Score: 0.114
-
An update on the molecular actions of fenofibrate and its clinical effects on diabetic retinopathy and other microvascular end points in patients with diabetes. Diabetes. 2013 Dec; 62(12):3968-75.
Score: 0.108
-
Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study. Diabetes Care. 2012 Feb; 35(2):218-25.
Score: 0.095
-
Uric acid predicts long-term cardiovascular risk in type 2 diabetes but does not mediate the benefits of fenofibrate: The FIELD study. Diabetes Obes Metab. 2020 08; 22(8):1388-1396.
Score: 0.042
-
Baseline Circulating FGF21 Concentrations and Increase after Fenofibrate Treatment Predict More Rapid Glycemic Progression in Type 2 Diabetes: Results from the FIELD Study. Clin Chem. 2017 Jul; 63(7):1261-1270.
Score: 0.035
-
Long-term fenofibrate therapy increases fibroblast growth factor 21 and retinol-binding protein 4 in subjects with type 2 diabetes. J Clin Endocrinol Metab. 2012 Dec; 97(12):4701-8.
Score: 0.025